Literature DB >> 23596297

The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.

Xueying Ma1, Ren-Huan Xu, Felicia Roscoe, J Charles Whitbeck, Roselyn J Eisenberg, Gary H Cohen, Luis J Sigal.   

Abstract

Orthopoxviruses (OPVs), which include the agent of smallpox (variola virus), the zoonotic monkeypox virus, the vaccine and zoonotic species vaccinia virus, and the mouse pathogen ectromelia virus (ECTV), form two types of infectious viral particles: the mature virus (MV), which is cytosolic, and the enveloped virus (EV), which is extracellular. It is believed that MVs are required for viral entry into the host, while EVs are responsible for spread within the host. Following footpad infection of susceptible mice, ECTV spreads lymphohematogenously, entering the liver at 3 to 4 days postinfection (dpi). Afterwards, ECTV spreads intrahepatically, killing the host. We found that antibodies to an MV protein were highly effective at curing mice from ECTV infection when administered after the virus reached the liver. Moreover, a mutant ECTV that does not make EV was able to spread intrahepatically and kill immunodeficient mice. Together, these findings indicate that MVs are sufficient for the spread of ECTV within the liver and could have implications regarding the pathogenesis of other OPVs, the treatment of emerging OPV infections, as well as strategies for preparedness in case of accidental or intentional release of pathogenic OPVs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596297      PMCID: PMC3676127          DOI: 10.1128/JVI.03158-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host.

Authors:  Min Fang; Luis J Sigal
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene.

Authors:  Lydia Aldaz-Carroll; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Lewis K Pannell; Jacob Lebowitz; Christiana Fogg; Christine L White; Bernard Moss; Gary H Cohen; Roselyn J Eisenberg
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

Review 3.  Progressive vaccinia.

Authors:  Mike Bray; Mary E Wright
Journal:  Clin Infect Dis       Date:  2003-02-20       Impact factor: 9.079

4.  Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.

Authors:  J W Hooper; D M Custer; E Thompson
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

Review 5.  Animal models of orthopoxvirus infection.

Authors:  J L Chapman; D K Nichols; M J Martinez; J W Raymond
Journal:  Vet Pathol       Date:  2010-08-03       Impact factor: 2.221

6.  Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice.

Authors:  G D Wallace; R M Buller
Journal:  Lab Anim Sci       Date:  1985-02

7.  A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.

Authors:  George W Buchman; Matthew E Cohen; Yuhong Xiao; Nicola Richardson-Harman; Peter Silvera; Louis J DeTolla; Heather L Davis; Roselyn J Eisenberg; Gary H Cohen; Stuart N Isaacs
Journal:  Vaccine       Date:  2010-07-24       Impact factor: 3.641

8.  Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.

Authors:  Lydia Aldaz-Carroll; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Lauren Hirao; Stuart N Isaacs; Bernard Moss; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

Authors:  Yuhong Xiao; Lydia Aldaz-Carroll; Alexandra M Ortiz; J Charles Whitbeck; Edward Alexander; Huan Lou; Heather L Davis; Thomas J Braciale; Roselyn J Eisenberg; Gary H Cohen; Stuart N Isaacs
Journal:  Vaccine       Date:  2006-10-17       Impact factor: 3.641

10.  Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Authors:  Felicia Roscoe; Ren-Huan Xu; Luis J Sigal
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

View more
  1 in total

1.  Evaluation of Virulence in Cynomolgus Macaques Using a Virus Preparation Enriched for the Extracellular Form of Monkeypox Virus.

Authors:  Eric M Mucker; Josh D Shamblin; Arthur J Goff; Todd M Bell; Christopher Reed; Nancy A Twenhafel; Jennifer Chapman; Marc Mattix; Derron Alves; Robert F Garry; Lisa E Hensley
Journal:  Viruses       Date:  2022-09-09       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.